BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37141264)

  • 1. Conjugating 4β-NH-(5-Aminoindazole)-podophyllotoxin and Galectin-1-Targeted Aptamer for Synergistic Chemo-Immunotherapy of Hepatocellular Carcinoma.
    Cong Y; Zhang SY; Tang PY; Li HM; Liu X; Zhao W; Tang YJ
    Adv Healthc Mater; 2023 Sep; 12(22):e2203144. PubMed ID: 37141264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
    Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
    PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
    Zhao W; He L; Xiang TL; Tang YJ
    Eur J Med Chem; 2019 May; 170():73-86. PubMed ID: 30878833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of Durvalumab/carbon nanotube/PEI/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma.
    Qiang N; Wei L; Tao Y; Jin W; Bin Y; DingHua Z
    Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
    J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Assembly of Podophyllotoxin-Loaded Lipid Bilayer Nanoparticles for Highly Effective Chemotherapy and Immunotherapy via Downregulation of Programmed Cell Death Ligand 1 Production.
    Wang R; Zhao Y; Huang Z; Zhou Y; Wang W; Xuan Y; Zhen Y; Ju B; Guo S; Zhang S
    ACS Nano; 2022 Mar; 16(3):3943-3954. PubMed ID: 35166522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models.
    Zhou Y; Fu C; Kong Y; Pan D; Wang Y; Huang S; Li Z; Ning Z; Lu X; Shan S; Xin L
    Anticancer Drugs; 2019 Oct; 30(9):909-916. PubMed ID: 30998512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
    Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
    J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy.
    Li W; Zhan M; Quan YY; Wang H; Hua SN; Li Y; Zhang J; Lu L; Cui M
    Int Immunopharmacol; 2020 Apr; 81():106227. PubMed ID: 32078941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
    Zhang L; Liu L; Zheng C; Wang Y; Nie X; Shi D; Chen Y; Wei G; Wang J
    Eur J Med Chem; 2017 May; 131():81-91. PubMed ID: 28301815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of 4beta-amido and 4beta-sulphonamido analogues of podophyllotoxin as potential antitumour agents.
    Kamal A; Ashwini Kumar B; Arifuddin M; Dastidar SG
    Bioorg Med Chem; 2003 Nov; 11(23):5135-42. PubMed ID: 14604676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
    Scherrer D; Barrett N; Teyton L; Pearce T; Nitcheu J; Pouletty P; Santo J; Ehrlich HJ
    Mol Cancer Ther; 2022 Dec; 21(12):1788-1797. PubMed ID: 36198025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.
    Su X; Yin H; Bai M; Liu J; Liu R; Zeng H; Wen J
    J Immunol; 2023 Mar; 210(5):681-695. PubMed ID: 36602827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on antitumor effects of podophyllotoxin nanoliposome].
    Zhang XY; Ni JM; Qiao H
    Zhongguo Zhong Yao Za Zhi; 2006 Jan; 31(2):148-50. PubMed ID: 16570806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiRNA-22 inhibits oncogene galectin-1 in hepatocellular carcinoma.
    You Y; Tan JX; Dai HS; Chen HW; Xu XJ; Yang AG; Zhang YJ; Bai LH; Bie P
    Oncotarget; 2016 Aug; 7(35):57099-57116. PubMed ID: 27494859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
    Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
    Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.